Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA federal legislation division

Executive Summary

Michael Reed, previously VP-government relations, to newly created post of senior legislative counsel in a reorganization of the federal legislation division announced May 9 by newly hired Executive VP-Strategic and Legislative Affairs Stephen Conafay. Deputy VP-Government Relations Lynda Nersesian will retain her title, as will legislative counsels Albert Saunders and Jeffrey Anders. Reed and Nersesian both will report to Conafay. Lara Robillaird -- formerly with Jones, Day, Reavis and Pogue, where Conafay held an of-counsel position before coming to PhRMA -- will join PhRMA as federal legislation associate. In announcing the changes, Conafay declares his intention to take an active, personal role in lobbying: "Mike Reed is one of the most respected and best-liked members of the legislative community, but I want to be directly involved in the daily federal legislative decisions and activities of PhRMA

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts